<DOC>
	<DOCNO>NCT02773550</DOCNO>
	<brief_summary>This clinical trial multicenter , cohort , one arm study SLP 18 month Velcadito scheme ( velcade 1.0 mg / m2 administer two day melphalan prednisone ) patient MM diagnosis high 75 . After completion protocol patient still approximately every two month , clinical practice , observe survival answer treatment . All scan part normal routine . The realization diagnostic test drug treatment perform regardless patient 's participation study part routine clinical practice All patient meet criterion . The incidence MM age-adjusted cover participate hospital estimate 44 patient . Patients receive course 4 week duration Melphalan / Prednisone / Velcade consist Melphalan , 9 mg / m2 orally daily 1-4 Prednisone 60 mg / m2 orally day 1 4 , combination Velcade dose 1.3 mg / m2 sc twice weekly ( day 1 , 4 , 8 , 11 ) , follow 2 week rest ( cycle duration 4 week ) seven four-week cycle duration melphalan / prednisone / Velcade consist Melphalan , 9 mg / m2 orally day 1 4 prednisone , 60 mg / m2 orally day 1 4 , combination Velcade , dose 1 , 0 mg / m2 sc ( day 1 , 4 ) . Melphalan Prednisone dispense oral administration . The Melphalan administer single two hour separately take food prednisone take morning immediately meal . The amount mg calculate base body surface , calculate day 1 cycle . Velcade administration , calculate day 1 cycle dose throughout entire cycle . If patient experience gain loss remarkable weight within cycle , dose administer recalculate base new body surface . The appropriate amount Velcadeserá dispense sc injection . Velcade dose two leave least 72 hour</brief_summary>
	<brief_title>Treatment With Scheme With Low Doses Bortezomib / Melphalan / Prednisone ( MPV ) Patients With Multiple Myeloma</brief_title>
	<detailed_description>This clinical trial multicenter , cohort , one arm study SLP 18 month Velcadito scheme ( velcade 1.0 mg / m2 administer two day melphalan prednisone ) patient MM diagnosis high 75 . After completion protocol patient still approximately every two month , clinical practice , observe survival answer treatment . All scan part normal routine . The realization diagnostic test drug treatment perform regardless patient 's participation study part routine clinical practice All patient meet criterion . The incidence MM age-adjusted cover participate hospital estimate 44 patient . Clinical Study Materials : - Melphalan present oral administration 2 mg tablet . - Prednisone present oral administration tablet 50 , 30 , 10 , 5 2.5 mg set correct dose administer . - Velcade.- ( Bortezomib ) subcutaneous administration . All study drug administer patient prescription investigator sub-investigators identify case Velcade dispense hospital Pharmacy Service Patients receive course 4 week duration Melphalan / Prednisone / Velcade consist Melphalan , 9 mg / m2 orally daily 1-4 Prednisone 60 mg / m2 orally day 1 4 , combination Velcade dose 1.3 mg / m2 sc twice weekly ( day 1 , 4 , 8 , 11 ) , follow 2 week rest ( cycle duration 4 week ) seven four-week cycle duration melphalan / prednisone / Velcade consist Melphalan , 9 mg / m2 orally day 1 4 prednisone , 60 mg / m2 orally day 1 4 , combination Velcade , dose 1 , 0 mg / m2 sc ( day 1 , 4 ) . Melphalan Prednisone dispense oral administration . The Melphalan administer single two hour separately take food prednisone take morning immediately meal . The amount mg calculate base body surface , calculate day 1 cycle . Velcade administration , calculate day 1 cycle dose throughout entire cycle . If patient experience gain loss remarkable weight within cycle , dose administer recalculate base new body surface . The appropriate amount Velcadeserá dispense sc injection . Velcade dose two leave least 72 hour</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>The patient , investigator 's opinion , able meet requirement trial . The patient must voluntarily sign informed consent perform test study part routine care patient , knowledge patient leave study time want , without harmed time aftercare . Age &gt; 75 year . The patient diagnose symptomatic multiple myeloma accord establish criterion may receive treatment disease ( see Appendix 6 ) . Administration permit steroid pulse urgency require prior start treatment induction administration bisphosphonates . The patient must measurable disease , define follow : For Multiple Myeloma secretory measurable disease define presence measurable serum monoclonal component , 1g/dL urinary excretion light chain great equal 200 mg/24 hour . For Multiple Myeloma oligosecretory secretory , serous level chain . Free light affect 10 mg/dL ( 100 mg/L , ratio abnormal free light chain serum ) . The patient must life expectancy great 3 month life . The patient must follow laboratory value prior initiation treatment correspond induction : Platelet count 50000/mm3 , hemoglobin 8 g/dl , absolute neutrophil count 1000/mm3 , Lower value permit due infiltration MO . Patients previously receive treatment multiple myeloma , exception steroid pulse urgency require prior initiate induction therapy , administration bisphosphonates radiotherapy either analgesic due presence plasmacytoma require urgency . Patients nonmeasurable disease SFLC . Patients know hypersensitivity bortezomib , boron mannitol acid . Patients receive investigational agent within 30 day prior enrollment . Patients currently another clinical trial receive investigational agent . Hypertension poorly control diabetes mellitus serious organic disease involve excessive risk patient psychiatric disorder interfere understand inform consent . Acute diffuse infiltrative pulmonary disease pericardial disease .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>